NCT07372508

Brief Summary

Lung cancer is one of the most common and serious cancers in Scotland and is often diagnosed at a late stage. Early detection is crucial to improving survival rates. The value of screening for lung cancer with low-dose CT (LDCT) scans has been established, and these scans can also identify other diagnoses earlier. Additional tests undertaken alongside the CT scan may add value to the lung cancer screening program being rolled out. This study aims to explore the feasibility and utility of a lung cancer screening program with added heart and breathing tests within a single clinic visit. A Lung Health Check will be offered to people at higher risk of lung cancer, specifically those aged 55-74 with a history of cigarette smoking. This will include a quick and painless LDCT scan, which uses a small amount of radiation to create detailed images of the lungs to detect lung cancer at an early and more treatable stage. In this "GALACTIC-1" study, the investigators will explore whether structured reporting of the CT scan, combined with additional tests (blood sample, ECG heart trace, and spirometry breathing test), can help identify conditions such as chronic obstructive pulmonary disease (COPD), lung scarring (pulmonary fibrosis), coronary artery disease, heart failure, and early signs of bone fractures (osteoporosis). This enhanced Lung Health Check may improve overall health by identifying and allowing early management of these conditions. The investigators plan to use the data from the "GALACTIC-1" study to explore AI performance by comparing it to reporting done by doctors. The results will help shape future rollout of lung cancer screening across Scotland, ensuring it is effective, efficient, and beneficial. The investigators will also have a focus group with patients and interviews with NHS staff to understand their opinions on the screening.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for not_applicable cancer

Timeline
29mo left

Started Mar 2026

Typical duration for not_applicable cancer

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress7%
Mar 2026Sep 2028

First Submitted

Initial submission to the registry

January 9, 2026

Completed
19 days until next milestone

First Posted

Study publicly available on registry

January 28, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

March 1, 2026

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 2, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 2, 2028

Last Updated

January 28, 2026

Status Verified

January 1, 2026

Enrollment Period

2.5 years

First QC Date

January 9, 2026

Last Update Submit

January 19, 2026

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

  • Proportion of eligible invited participants who receive all components of the combined low-dose CT (LDCT) screening and AI-assisted cardiorespiratory diagnostic tests within the study active period.

    Number of patients successfully screened per protocol within recruitment timelines

    6 months

Secondary Outcomes (13)

  • Sensitivity of LDCT for detecting confirmed lung cancer (proportion of patients with lung cancer correctly identified as positive).

    Baseline

  • Specificity of LDCT for detecting confirmed lung cancer (proportion of patients without lung cancer correctly identified as negative).

    Baseline

  • Lung cancer detection rate

    Baseline

  • Stage distribution of detected lung cancers

    Baseline

  • Detection rate of undiagnosed COPD and/or emphysema in participants.

    Baseline

  • +8 more secondary outcomes

Study Arms (1)

All patients

OTHER

All patients

Diagnostic Test: Low dose Chest CT

Interventions

Low dose Chest CTDIAGNOSTIC_TEST

Low dose Chest CT

All patients

Eligibility Criteria

Age55 Years - 74 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Resident in South Sector NHS GG\&C.
  • Capacity to undertake informed consent.
  • No active cancer other than non-melanoma skin cancer, monitored localised prostate cancer or localised treated breast cancer.
  • Aged 55-74 at date of invitation.
  • Smoking history: current tobacco smoker or ex-smoker with \>20 pack year history and \<15 years from quit date.

You may not qualify if:

  • CT thorax scan undertaken in prior 12 months.
  • Does not have capacity to give consent (standard criteria for assessing capacity apply).
  • Aged \<55 or \>74 years of age at date of invitation
  • Weight exceeds restrictions for scanner (\>200kg).
  • Unable to lie flat.
  • People who are pregnant.
  • Active symptoms of possible lung cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Queen Elizabeth University Hospital

Glasgow, United Kingdom

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Chris Carlin

    NHSGGC

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Clare Dolan

CONTACT

0141 314 4328clare.dolan3@nhs.scot

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 9, 2026

First Posted

January 28, 2026

Study Start

March 1, 2026

Primary Completion (Estimated)

September 2, 2028

Study Completion (Estimated)

September 2, 2028

Last Updated

January 28, 2026

Record last verified: 2026-01

Locations

GB(1)